Themis Medicare releases pledge on 1.65 million shares of Gujarat Themis Biosyn

What Themis Medicare announced

Themis Medicare Limited, acting as promoter of Gujarat Themis Biosyn Limited, disclosed that it had released a pledge on 1,650,000 equity shares of the target company. The release took place on 8 July 2026 and was reported to the stock exchanges on 16 July 2026 in compliance with Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing confirms that the pledged shares represented 1.51 % of the total share capital of Gujarat Themis Biosyn Ltd.

Details of the pledge release

The filing, addressed to both BSE and NSE, provides a tabular breakdown of the promoter’s shareholding and the encumbrance status before and after the event. Prior to the release, Themis Medicare Ltd held 227,74,847 shares, amounting to 20.90 % of the target’s capital. Of this holding, 1,650,000 shares (1.51 % of total capital) were under a pledge. The release on 8 July 2026 removed the pledge entirely, leaving the promoter’s shareholding unencumbered. No new pledge, lien, non‑disposal undertaking or other form of encumbrance was created in connection with this transaction.

Regulatory framework under SEBI Regulation 31

Regulation 31 of the SEBI (SAST) Regulations, 2011 mandates that promoters disclose any creation, release or invocation of encumbrances on shares of a target company. The disclosure must be made to the stock exchanges where the target is listed and to the target itself, using a prescribed format. The filing satisfies these requirements by:

• Naming the promoter (Themis Medicare Ltd) and the target (Gujarat Themis Biosyn Ltd).
• Stating the exact number of shares affected and the percentage of total share capital.
• Specifying the type of encumbrance (pledge) and the date of release (08/07/2026).
• Confirming that the event is a release, not a creation or invocation. The filing was signed by Dr Sachin D Patel, Managing Director & CEO of Themis Medicare Ltd, and dated 16 July 2026.

Shareholding and encumbrance statistics

Why this matters for investors

The release of a pledge reduces the risk of forced sale of the pledged shares, which could otherwise affect market perception and liquidity. For shareholders of Gujarat Themis Biosyn Ltd, the removal of the encumbrance signals that the promoter’s stake is now fully free of security interests, potentially enhancing confidence in the promoter’s commitment to the company. From a regulatory standpoint, the timely disclosure demonstrates compliance with SEBI’s transparency requirements, thereby maintaining the integrity of the market’s information flow. No dilution or capital‑raising activity is associated with this filing; the event solely concerns the status of existing shares.

"Themis Medicare Ltd released a pledge on 1,650,000 equity shares of Gujarat Themis Biosyn Ltd on 8 July 2026, representing 1.51 % of the target’s share capital," (BSE filing, 16 July 2026).

Conclusion

The filing confirms that Themis Medicare Ltd has fully released a pledge covering 1.65 million shares of Gujarat Themis Biosyn Ltd, reducing the encumbered portion of its 20.90 % stake to zero. The disclosure satisfies SEBI’s Regulation 31 requirements and was communicated to both BSE and NSE on 16 July 2026. No further encumbrance or corporate action related to this shareholding has been indicated in the filing.